Project description
Innovative stent to treat critical limb ischemia
Below-the-knee critical limb ischemia (BTK-CLI) is a severe arterial blockage condition affecting over 3.5 million people in the EU and the United States. Current treatments such as balloon angioplasty often lead to complications, restenosis or even limb amputations. The EIC-funded EX-STENT project is developing an innovative stent made of nanofibres to treat BTK-CLI. The new stent presents a paradigm shift as it dissolves gradually while forming new vascular tissue, fully rebuilding the artery to secure long-term patency. The Netherlands-based company receiving the EU funding, STENTIT B.V. is presently seeking EUR 2.5 million in grants and EUR 10 million in equity to finalise clinical studies and prepare for market launch of its regenerative stent.
Objective
Below-the knee critical limb ischemia (BTK-CLI) is the severe blockage of the arteries in the limb, leading to reduced blood flow. This condition currently affects over +3.5M people in the EU and US. The current standard of care for BTK-CLI is balloon angioplasty. This treatment unfortunately has failed to show strong clinical outcomes: around 40% of patients suffer from procedural complications, 73% of the cases develop restenosis within 3 months and 25% of patients end up requiring minor or major limb amputations. STENTiT has developed a first-in-class stent with regenerative capacity, a paradigm shift for medical stents. The Regenerative Stent is fully composed of nanofibers which allows for unique vascular restoration. The stent gradually dissolves while new vascular tissue is being formed, fully rebuilding the artery to secure long-term patency. STENTiT requests a €2.5M grant and €10M in equity to complete the clinical studies and prepare the Regenerative Stent for market launch.
Keywords
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinator
5656 AE Eindhoven
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.